Dosing and uses of Infasurf (calfactant)
Adult dosage forms and strengths
Not indicated
Pediatric dosage forms and strengths
intratracheal suspension
- 3mL
- 6mL
Respiratory Distress Syndrome
3 mL/kg (birth weight) intratracheal q12hr up to 3 doses
Administration
Intratracheally thru side-port adapter of ETT in 2 equal aliquots
Store vial in fridge, may swirl to redistribute, warming not necessary
Infasurf (calfactant) adverse (side) effects
>10%
Cyanosis (65%)
Airway obstruction (39%)
Bradycardia (34%)
Reflux into ETT (21%)
Requirement for manual ventilation (16%)
1-10%
Reintubation (3%)
Warnings
Cautions
Infant may exhibit bradycardia, reflux, cyanosis, airway obstruction, ETT dislodge, hypoventilation
Do not chill & thaw more than once; single-use vials; keep 3 mL vial upright
Pregnancy and lactation
Pregnancy category: N/A
Lactation: N/A
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
